Table 4.

Crude and adjusted daily decline among different subgroups.

Group	N	Crude Daily Change of CTC in 3 Days	95%CI		p-Value	Adjusted Daily Change of CTCs in 3 Days	95%CI		p-Value	p-Value for Interaction
Total	50	−2.1129	−3.2998	−0.9259	0.0008	−2.1262	−3.2806	−0.9718	0.0005
Sex
Male	28	−1.9206	−3.0995	−0.7416	0.0025	−1.9397	−3.0756	−0.8038	0.0017	0.7046
Female	22	−2.3692	−4.6379	−0.1006	0.0415	−2.3692	−4.6228	−0.1156	0.0403
Malignancy vs. Benign
Benign	4	−0.3786	−1.1618	0.4047	0.2216	−0.3786	−1.1566	0.3995	0.2193	0.3665
Malignant	46	−2.2637	−3.5444	−0.9831	0.0009	−2.2803	−3.5361	−1.0245	0.0007
Metastasis vs. Benign
Benign	4	−0.3786	−1.1618	0.4047	0.2216	−0.3786	−1.1566	0.3995	0.2193	0.8660
Metastatic	5	−2.5543	−6.8846	1.7761	0.1768	−2.5543	−6.2984	1.1899	0.1311
Lung cancer without recurrence	30	−2.5359	−4.3652	−0.7065	0.0083	−2.5702	−4.3728	−0.7676	0.0068
Lung cancer with recurrence	11	−1.4000	−3.1405	0.3405	0.1033	−1.4000	−2.9854	0.1854	0.0775
Stages
Benign entity	4	−0.3786	−1.1618	0.4047	0.2216	−0.3786	−1.1566	0.3995	0.2193	0.8242
Stage I and Tis	26	−2.8526	−4.8985	−0.8068	0.0082	−2.8526	−4.8892	−0.8161	0.0079
Stage II	6	−1.5586	−4.2542	1.1371	0.1974	−1.5586	−4.1012	0.9840	0.1759
Stage III	8	−0.07411	−1.9415	1.7932	0.9258	−0.08582	−1.3883	1.2167	0.8772
Stage IV	6 a	−3.1952	−6.7311	0.3406	0.0678	−3.1952	−6.6038	0.2133	0.0609

^a Stage IV group included 5 metastatic cancers and one stage IVc lung cancer. CTC, circulating tumor cells; CI, confidence interval.